by As advancements in gene sequencing technologies continue to expand our knowledge of cellular diversity, researchers at St. Jude Children’s Research Hospital have introduced a novel tool to facilitate the targeted study of specific subgroups of cells. Dubbed Conditional Viral Expression by Ribozyme Guided Degradation (ConVERGD), this innovative technology enables scientists to selectively access and control these neuronal subpopulations based on various cellular characteristics.
ConVERGD represents a significant improvement over existing intersectional expression platforms due to its ability to accommodate more intricate genetic payloads and heightened adaptability. In a recent study, researchers employed ConVERGD to explore a previously unknown subclass of norepinephrine neurons.
The groundbreaking research highlights the potential far-reaching implications of investigating neuronal subpopulations in fundamental research and healthcare applications. The findings were published in the May 27 issue of Nature Neuroscience Neuroregeneration therapy.
Scientists at St. Jude Children’s Research Hospital have developed a new tool, ConVERGD, which allows researchers to selectively access and manipulate specific subpopulations of neurons based on multiple cellular features. This technology offers advantages over existing intersectional expression platforms and has the potential to significantly impact fundamental research and healthcare applications. The researchers demonstrated the utility of ConVERGD by studying a previously unidentified subclass of norepinephrine neurons. The findings from this study were published in the journal Nature Neuroscience on May 27.
